<DOC>
	<DOCNO>NCT00006215</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . Colony-stimulating factor filgrastim may increase number immune cell find bone marrow peripheral blood may help person 's immune system recover side effect chemotherapy . PURPOSE : Phase II trial study effectiveness combination chemotherapy plus filgrastim treating patient stage IIIB stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>Docetaxel Vinorelbine Plus Filgrastim Treating Patients With Stage IIIB Stage IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response docetaxel vinorelbine filgrastim ( G-CSF ) support patient stage IIIB IV non-small cell lung cancer . II . Determine toxicity regimen patient . III . Determine overall survival time tumor progression patient treat regimen . OUTLINE : This multicenter study . Patients receive vinorelbine IV 6-10 minute docetaxel IV 1 hour day 1 filgrastim ( G-CSF ) subcutaneously daily day 2-12 blood count recover . Treatment continue every 2 week absence disease progression unacceptable toxicity . Patients follow every 3 month . PROJECTED ACCRUAL : A total 60 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm stage IIIB IV nonsmall cell lung cancer Bidimensionally measurable evaluable disease No symptomatic brain metastasis PATIENT CHARACTERISTICS : Age : Over 18 Performance status : Karnofsky 70100 % Life expectancy : Greater 2 month Hematopoietic : Absolute neutrophil count least 2,000/mm3 Platelet count least 100,000/mm3 Hepatic : AST ALT great 1.5 time upper limit normal ( ULN ) Bilirubin great ULN Renal : Creatinine great 2.0 mg/dL Cardiovascular : No uncontrolled hypertension , unstable angina , congestive heart failure , atrial ventricular arrhythmia At least 6 month since prior myocardial infarction Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No poorly control diabetes No known allergy E. coli derivative product administer No prior malignancy within past 5 year except surgically cure basal cell skin cancer carcinoma situ cervix No active infection fever Not previously enter study PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent hematopoietic growth factor Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 2 week since prior radiotherapy recover Surgery : At least 2 week since prior major thoracic abdominal surgery recover At least 6 month since prior coronary angioplasty Other : At least 30 day since prior investigational agent No concurrent investigational agent No prophylactic acetaminophen fever</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2001</verification_date>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>